Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

被引：6
|
作者：
Jaeger, Ulrich
Worel, Nina
McGuirk, Joseph
Riedell, Peter A.
Fleury, Isabelle
Borchmann, Peter
Du, Yan
Abdelhady, Ahmed M.
Han, Xia
Martinez-Prieto, Marcela
Waller, Edmund K.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA
[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Hop Maisonneuve Rosemont, Dept Med Specialisee, Hematooncol, Montreal, PQ, Canada
[5] Klinikum Univ Koln, Cologne, Germany
[6] Novartis Pharma AG, Shanghai, Peoples R China
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
[8] Emory Clin, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19537
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] y Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph P.
    Riedell, Peter A.
    Fleury, Isabelle
    Borchmann, Peter
    Chu, Jufen
    Abdelhady, Ahmed M.
    Forcina, Alessandra
    Pacaud, Lida Bubuteishvili
    Waller, Edmund K.
    BLOOD, 2019, 134
  • [3] Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph P.
    Riedell, Peter A.
    Fleury, Isabelle
    Du, Yan
    Han, Xia
    Pearson, David
    Redondo, Santiago
    Waller, Edmund K.
    BLOOD ADVANCES, 2023, 7 (11) : 2283 - 2286
  • [4] Efficacy and safety of Tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 ELARA trial
    Schuster, S.
    Dickinson, M.
    Dreyling, M.
    Martinez-Lopez, J.
    Kolstad, A.
    Butler, J.
    Ghosh, M.
    Popplewell, L.
    Chavez, J.
    Bachy, E.
    Kato, K.
    Harigae, H.
    Kersten, M. J.
    Andreadis, C.
    Riedell, P.
    Zia, A.
    Morisse, M. C.
    Fowler, N. H.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 104 - 105
  • [5] Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
    Schuster, Stephen J.
    Dickinson, Michael J.
    Dreyling, Martin H.
    Martinez, Joaquin
    Kolstad, Arne
    Butler, Jason Paul
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Abdelhady, Ahmed M.
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [7] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Borchmann, P.
    Tam, C. S.
    Jaeger, U.
    McGuirk, J. P.
    Holte, H.
    Waller, E. K.
    Jaglowski, S. M.
    Bishop, M. R.
    Andreadis, C.
    Foley, S. R.
    Westin, J. R.
    Fleury, I.
    Ho, P. J.
    Mielke, S.
    Salles, G.
    Maziarz, R. T.
    Anak, Oe
    Pacaud, L. B.
    del Corral, C.
    Awasthi, R.
    Agoulnik, S.
    Tai, F.
    Schuster, S. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 36 - 37
  • [10] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Giri, Pratyush
    Patil, Sushrut
    Ratnasingam, Sumita
    Prince, H. Miles
    Milliken, Samuel
    Meijide, Javier Briones
    Coyle, Luke
    Van der Poel, Marjolein
    Mulroney, Carolyn M.
    Farooqui, Mohammed Z. H.
    Wong, Hansen
    Desai, Rajendra
    Zugmaier, Gerhard
    Mergen, Noemi
    Cannell, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345